| Autor: |
Rambeau A; Medical Oncology Department, Centre François Baclesse, Av général Harris, 14000, Caen, France. audrey.rambeau@gmail.com., Gervais R; Medical Oncology Department, Centre François Baclesse, Av général Harris, 14000, Caen, France., De Raucourt D; Department of Head and Neck Surgery, Centre François Baclesse, 14000, Caen, France., Babin E; Department of Head and Neck Surgery, Centre Hospitalier Universitaire, 14000, Caen, France., Dugué AE; Clinical Research unit, Centre François Baclesse, 14000, Caen, France., Florescu C; Department of Radiotherapy, Head and Neck Unit, Centre François Baclesse, 14000, Caen, France., Blanchard D; Department of Head and Neck Surgery, Centre François Baclesse, 14000, Caen, France., Gery B; Department of Radiotherapy, Head and Neck Unit, Centre François Baclesse, 14000, Caen, France. |
| Abstrakt: |
Radiotherapy associated with cetuximab (Cet-RT) is an alternative treatment to platinum-based chemoradiotherapy in locally advanced head and neck carcinoma (LAHNC). Reviews suggest that the use of cetuximab is associated with poorer tolerance in patients unfit for chemotherapy than in pivotal trial. We retrospectively studied patients first treated by Cet-RT for LAHNC presenting contraindications to chemoradiotherapy. Objectives were treated population description, acute tolerance, progression-free survival (PFS), overall survival (OS), and 3-month clinical response. Eighty-eight patients were included. Treatment was completed without delay for 43 patients. Grade 3-4 acute toxicity was described in 44.3%: mucositis (n = 20), radiodermatitis (n = 25) folliculitis (n = 10), and anaphylaxis (n = 6). Fourteen patients died during treatment. Median PFS and OS were 6.3 and 18.7 months, respectively. We confirm that Cet-RT tolerance in unfit patients is poorer than that in trials. Survival data illustrate patients' frailty and suggest that balanced use of Cet-RT is required in this population. |
Full text from SpringerLink